• FedEx for ultra-cold biopharma shipments.
• AWS for advanced therapy cold chain.

• Cryoport Express® Cold Chain Logistics: This service provides integrated, validated logistics for temperature-sensitive biological materials, including advanced therapies, using specialized cryogenic shipping containers and real-time monitoring across a global network.
• MVE Biological Solutions Cryogenic Equipment: Manufactures and supplies stainless steel cryogenic storage equipment, such as dewars and freezers, for long-term preservation of biological materials and industrial gas applications.

• Pharmaceutical Companies: Large and small pharmaceutical companies developing and commercializing drugs, especially biologics and advanced therapeutic medicinal products (ATMPs), which require precise temperature control during storage and transport for clinical trials and commercial distribution.
• Biotechnology Companies: Firms specializing in biotechnology research and development, particularly those involved in novel therapies like cell, gene, and immunotherapies, which rely heavily on ultra-low temperature cryogenic logistics for their critical materials and products.
• Contract Research Organizations (CROs): Companies that provide outsourced research services to the pharmaceutical, biotechnology, and medical device industries. CROs often manage clinical trials that involve the transport of highly sensitive biological samples and therapies, utilizing CryoPort's specialized cold chain solutions.
• Academic and Research Institutions: Universities, research laboratories, and hospitals involved in cutting-edge biological research, clinical studies, and the development of new therapies often require secure and compliant cryogenic transport for their research materials and patient samples.
• Healthcare Providers: Hospitals, specialized clinics, and other healthcare facilities that administer advanced therapies to patients, requiring reliable and safe transport of these delicate products from manufacturing sites to the point of care.

• FedEx Corporation (Symbol: FDX)
• United Parcel Service, Inc. (Symbol: UPS)
• Deutsche Post AG (operating DHL Express) (Symbol: DPW.DE / DPSGY)
• AmerisourceBergen Corporation (operating World Courier) (Symbol: ABC)

Jerrell W. Shelton, President and Chief Executive Officer, Chairman

Jerrell Shelton has over 40 years of executive and corporate governance experience across various industries, including information services, software, telecommunications, manufacturing, natural resources, and distribution. He joined Cryoport's board in October 2012 and was appointed President and CEO in November 2012, becoming Chairman of the Board in October 2015. Prior to Cryoport, he served as President and CEO of several companies, including NDC Holdings, Continental Graphics Holdings, Thomson Business Information Group, and Advantage Companies. Under his leadership, these companies achieved rapid revenue growth, improved profitability, and increased shareholder value. He was also a visiting executive at IBM Research, where he contributed to the creation and development of WebFountain.

Robert S. Stefanovich, Chief Financial Officer and Treasurer

Robert Stefanovich possesses more than 30 years of experience in financial management and strategy, including over 20 years as CFO in the specialty pharma, medical device, and software sectors. He has served as CFO for Novalar Pharmaceuticals, a venture-backed specialty pharmaceutical company, and as CFO for three publicly traded companies: Xcorporeal (a medical device company), Artemis International Solutions Corporation (a software company), and Aethlon Medical (a medical device company). Earlier in his career, he was Vice President of Administration at SAIC.

Mark W. Sawicki, Ph.D., Chief Scientific Officer

Dr. Mark Sawicki has over 20 years of executive and sales management experience, consistently achieving corporate revenue and market share goals in the pharmaceutical and biotechnology industries. Before his current role, he was the chief business officer at Alcami and held senior business development positions at AGC Biologics and Curia, where he significantly increased revenue. He also served as President and Chief Executive Officer of Cryoport Systems, LLC, and Chief Commercial Officer at Cryoport Systems.

Tony Ippolito, Vice President, General Counsel and Corporate Secretary

Tony Ippolito has more than 18 years of experience in mergers and acquisitions, securities law, and general corporate law. Prior to joining Cryoport, he was a partner in the Corporate and Securities practice group at Snell & Wilmer, LLP, where he advised reporting companies on securities law matters, M&A, private placements, venture capital financings, and owner buyouts.

Kylie Crowe, Vice President, Global Human Resources & Organizational Development

Kylie Crowe has over 20 years of experience in Human Resources, with more than 15 years as a global senior-level HR executive in the clinical research, medical devices, and healthcare industries. Before joining Cryoport, she was the Global HR Director at Covance Inc.

The clear emerging threat to CryoPort (CYRX) is the increasing investment and aggressive expansion by larger, integrated global logistics providers (such as UPS Healthcare/Marken, FedEx Healthcare, and DHL Life Sciences) into the highly specialized ultra-cold chain logistics market for cell and gene therapies. These companies are leveraging their immense resources, existing global networks, and comprehensive logistics infrastructure to develop and offer services that directly compete with CryoPort's niche, potentially eroding its market share and pricing power over time as they enhance their specialized capabilities in this high-growth sector.

• Growth in Commercial Cell and Gene Therapies: CryoPort continues to experience significant revenue growth from its support of commercial cell and gene therapies, with a 36% year-over-year increase in Q3 2025 alone. As a pure-play end-to-end temperature-controlled supply chain platform, CryoPort is positioned to benefit from the ongoing global adaptation and increasing number of these life-saving therapies reaching commercialization. This segment is anticipated to be a primary driver of growth for years to come.
• Expansion of Life Sciences Services, particularly BioStorage/BioServices: The Life Sciences Services segment, which includes BioStorage/BioServices, has demonstrated consistent double-digit growth, with a 16% year-over-year increase in Q3 2025 and a 21% rise in BioStorage/BioServices revenue. This growth is attributed to the persistent demand for CryoPort's integrated platform, the introduction of expanded capabilities to existing customers, and the addition of new clients to its global network.
• Increasing Portfolio of Clinical Trials Progressing to Commercialization: CryoPort supports a substantial and growing number of global clinical trials in regenerative medicine, including 745 active clinical trials as of Q3 2025, with 83 of them in Phase 3. This extensive clinical trials pipeline represents a significant long-term revenue growth opportunity as more therapies advance through the clinical stages and gain regulatory approvals to become commercial therapies. For 2025, the company anticipates up to 23 additional application filings, five new therapy approvals, and five approvals for label/geographic expansions or moves to earlier lines of treatment.
• Launch of New and Advanced Life Sciences Products: CryoPort's Life Sciences Products segment also contributes to revenue growth, with a 15% year-over-year increase in Q3 2025. This is driven by improved demand for its cryogenic systems and the strategic launch of new products. For example, in Q3 2025, CryoPort expanded its product portfolio with the introduction of the MVE Biological Solutions next-generation SC4/2V and SC4/3V vapor shippers, which feature innovative technologies for enhanced protection and integrated condition monitoring.
• Strategic Partnerships and Global Infrastructure Expansion: CryoPort is actively expanding its global footprint and enhancing service delivery through strategic initiatives. The company's strategic partnership with DHL Group is expected to strengthen its positioning in the EMEA and APAC regions. Additionally, CryoPort has been expanding its global infrastructure, including the opening of the logistics portion of its new global supply chain center at Charles de Gaulle Airport in Paris and onboarding clients for IntegriCell in Belgium and Houston. These expansions aim to better serve clients and diversify revenue streams.

Share Repurchases

• Cryoport authorized a repurchase program on March 11, 2022, to purchase up to $100.0 million in common stock and/or convertible senior notes through December 31, 2025.
• During 2022, $37.9 million was spent to repurchase 1,604,994 shares of common stock under this program.
• On August 6, 2024, a new $200 million repurchase program was authorized, and the company repurchased $160 million in aggregate principal amount of its 0.75% Convertible Senior Notes due in 2026 for $141.6 million.

Share Issuance

• In January 2021, Cryoport completed a public offering of 4,356,059 shares of common stock at $66.00 per share, resulting in gross proceeds of approximately $287.5 million and net proceeds of approximately $234.5 million, intended for general corporate purposes and infrastructure expansion.
• In October 2020, Cryoport issued $25 million of common stock in a private placement to funds affiliated with The Blackstone Group Inc. in conjunction with the MVE Biological Solutions acquisition.

Inbound Investments

• In October 2020, funds affiliated with The Blackstone Group Inc. invested $250 million in newly designated Series C Convertible Preferred Stock in Cryoport.

Outbound Investments

• In October 2020, Cryoport acquired MVE Biological Solutions and CRYOPDP. The CRYOPDP acquisition was for approximately €49 million (reported as under $57 million).
• In April 2021, Cryoport acquired Critical Transport Solutions Australia Pty Ltd (CTSA) for approximately $5 million, integrating it into its CRYOPDP business unit.
• In March 2025, Cryoport announced a strategic partnership with DHL Group, which included DHL's acquisition of CRYOPDP from Cryoport for an enterprise valuation of $195 million.

Capital Expenditures

• Capital expenditures for the second quarter of 2025 were $4.4 million.
• Cryoport has opened a new global supply chain center at Charles de Gaulle Airport in Paris.
• The company plans to open another Global Supply Chain Center in Santa Ana, California, in the second half of 2026, consolidating three existing locations and featuring next-generation technology.